SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq:XNPT) announced today that it will report several developments in its XP19986 and XP13512 clinical programs at the JPMorgan 25th Annual Healthcare Meeting. These advancements include identification of a new tablet formulation for XP19986 that may be suitable as a once-a-day treatment for gastroesophageal reflux disease, or GERD, as well as updates on clinical trials that are part of XenoPort’s XP13512 development program.
